Michael P. Cooreman
Direttore Tecnico/Scientifico/R&S presso INVENTIVA
Patrimonio netto: 53 819 $ in data 31/05/2024
Profilo
Michael P.
Cooreman is currently the Chief Medical Officer at Inventiva SA since 2020.
Prior to this, he was the Vice President-Science & Medicine at Ferring Pharmaceuticals, Inc. from 2017 to 2020 and the Chief Medical Officer at ImmusanT, Inc. from 2015 to 2017.
He holds a doctorate degree from Heinrich-Heine-Universität Düsseldorf and Université Catholique de Louvain.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
INVENTIVA SA
0.03% | 01/03/2024 | 15 000 ( 0.03% ) | 53 819 $ | 31/05/2024 |
Posizioni attive di Michael P. Cooreman
| Società | Posizione | Inizio |
|---|---|---|
| INVENTIVA | Direttore Tecnico/Scientifico/R&S | 01/11/2020 |
Precedenti posizioni note di Michael P. Cooreman
| Società | Posizione | Fine |
|---|---|---|
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Corporate Officer/Principal | 01/01/2020 |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2017 |
Formazione di Michael P. Cooreman
| Université Catholique de Louvain | Doctorate Degree |
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INVENTIVA | Health Technology |
| Aziende private | 2 |
|---|---|
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
- Borsa valori
- Insiders
- Michael P. Cooreman
